DSPE-PEG-Amine，DSPE-PEG-NH2

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)]

Synonym: DSPEPEG NH2, Amino PEG DSPE, Amine PEG DSPE, NH2 PEG DSPE.

ProductStructure:

ProductSpecifications:

l CatalogNumbers:PS2-NDE-1K,2K,3K,5K,10K.

l Appearance: Whiteto off-white solid.

l Solubility: >10mg/mL in hot water, chloroform, DCM.

l Stability: 1 Years at-20°C, Desiccate.

l CASNumber: 474922-26-4.

l MolecularWeight（PEG）:1K,2K,3.4K,5K,10K.

l Reactivegroup: Amine (-NH2).

l Reactiveto: Carboxylic acid group (-COOH,NHS,CHO).

l Purity: 95%.

Description:

DSPE PEG amine is one ofPonsure reactive phospholipid PEG derivatives that have a primary amine groupand a DSPE phospholipid bridged by a linear PEG linker. DSPE(1,2-distearoyl-sn-glycero-3-phosphoethanolamine) is an 18 carbon phospholipidthat is highly hydrophobic. PEG backbone, on the other hand, offers good hydrophilicityand water solubility. Amine PEG DSPE is one of most commonly used reactive phospholipids to conjugate antibodies,peptides or other ligands to the surface of liposome and other lipid PEGnanoparticles. Ponsure has developed a comprehensive collection of chemicalreactive phospholipid PEG products that have high purity, various molecularweights and excellent chemical reactivity. These lipid PEG conjugatesdemonstrate excellent amphilphilic properties and offer superior advantages forsmall and large molecule modification, formulation and delivery.

Handlingand Use:

DSPEPEG amine should always be kept in low temperature in dry condition. Prepare freshsolution right before use.Avoid frequent thaw and freezing. For moreinformation about using this product,  visit www.ponsure.com.

RelatedProducts:

DSPE-PEG-N3,DSPE-PEG-COOH

DSPE-PEG-NHS,DSPE-PEG-FA

DSPE-PEG-SH,DSPE-PEG-MAL

References：

l Theranostics(IF=8.537)------GSH-sensitivePt(IV) prodrug-loaded phase-transitional nanoparticles with a hybridlipid-polymer shell for precise theranostics against ovarian cancer.

l Journal ofControlled Release(IF=7.877)-----Zinc phthalocyanine-soybean phospholipidcomplex based drug carrier for switchable photoacoustic/fluorescence image,multiphase photothermal/photodynamic treatment and synergetic therapy.

l InternationalJournal of Nanomedicine(IF=4.37)------A GPC3-specific aptamer-mediated magneticresonance probe for hepatocellular carcinoma.

l Cryoprotectantchoice and analyze of freeze-drying drug suspension of nanoparticles withfunctional stabilizers.

l 808 nm Light Responsive Nanotheranostic Agents Based on Near-infrared Dye Functionalized Manganese Ferrite for Magnetic‐targeted and Imagingguided Photodynamic/Photothermal Therapy-----Journal of MaterialsChemistry B(IF=4.776)

l Light/magnetichyperthermia triggered drug released from multi-functional thermo-sensitivemagnetoliposomes for precise cancer synergetic theranostics------ Journalof Controlled Release(IF=7.877)

l A novelnear-infrared triggered dual-targeted nanoplatform for mitochondrial combinedphotothermal-chemotherapy of cancer in vitro------ Nanotechnology(IF=.404)

l Folate-decoratedand NIR-triggered nanoparticles loaded with platinum(IV)-prodrug plus5-fluorouracil for targeted and chemo-photothermal combination therapy.

l Noveltheranostic zinc phthalocyanine–phospholipid complex self-assembled  nanoparticles for  imaging-guided  targeted photodynamic treatment withcontrollable ROS production and shape-assisted enhanced cellular uptake------ Colloidsand Surfaces B: Biointerfaces(IF=3.997)

l αvβ3 integrinreceptor specific peptide modified, salvianolic acid B and panaxnotoginsenoside loaded nanomedicine for the combination therapy of acutemyocardial.

Thisproduct is for research use only and is not intended for use in humans or fordiagnostic use.